Status: Recruiting
Study of Treatment for HPV16+ ASC-US or LSIL
Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
Participants needed: 30
Trial details
Phase: Phase 1Age: 19+Biological sex: FemaleType: InterventionalSponsor: University of Alabama at BirminghamUpdated: May 15, 2026Locations: 2
Eligibility criteria
Patients with persistent (>6 month period) ASC-US/LSIL determined by cervical cy... [+14]
Patients with ASC-US/LSIL determined by cervical cytology at study entry that ar... [+12]